Why insider trading matters?
If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.
Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types.
| Trade Date | Insider | Title | Buy/Sell | #Shares | Price | Value | Option |
|---|---|---|---|---|---|---|---|
| 2021-12-01 | Jones Erin | Chief Operating Officer | Sell | 1,000 | $13.01 | $13,010 | Yes |
| 2021-11-01 | Jones Erin | Chief Operating Officer | Sell | 1,000 | $11.14 | $11,140 | Yes |
| 2021-10-04 | Jones Erin | nan | Sell | 2,000 | $10.70 | $21,390 | Yes |
| 2021-09-08 | Jones Erin | nan | Sell | 2,000 | $11.37 | $22,748 | Yes |
| 2021-11-01 | Jones Erin | nan | Sell | 1,000 | $11.14 | $11,140 | Yes |
| 2021-10-04 | Jones Erin | nan | Sell | 2,000 | $10.70 | $21,390 | Yes |
| 2021-05-27 | Rousseau Raphael | nan | Sell | 2,900 | $9.00 | $26,112 | Yes |
| 2021-01-20 | Rousseau Raphael | nan | Sell | 30,000 | $20.04 | $601,269 | Yes |
| 2021-01-19 | Yelensky Roman | nan | Sell | 10,000 | $22.10 | $221,029 | No |
| 2020-12-30 | Woiwode Thomas | Director | Buy | 1,347,709 | $3.71 | $5,000,000 | No |
| 2019-08-21 | Rousseau Raphael | See Remarks | Sell | 10,000 | $10.76 | $107,631 | Yes |
| 2018-09-28 | Simon Nicholas | 10%-Owner, Director | Buy | 333,333 | $15.00 | $4,999,995 | Yes |
| 2018-09-28 | Clarus Lifesciences III, L.P. | 10%-Owner | Buy | 333,333 | $15.00 | $4,999,995 | Yes |
Insider Smart
Insider Smart